The Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Substance Use Disorder (SUD)-related Behavioural Effects of Drugs and Alcohol: A Systematic Review

Overview

Journal Physiol Behav

Specialties Physiology
Psychiatry
Psychology
Social Sciences

Date 2019 Apr 5

PMID 30946836

Citations 13

Authors

Amanda Brunchmann

Morgane Thomsen

Anders Fink-Jensen

Affiliations

Soon will be listed here.

Abstract

Glucagon-like-peptide-1 (GLP-1)-receptor agonists have been proposed as putative treatment for substance use disorders (SUD). The objective of this systematic review is to characterize the effects of GLP-1-receptor agonists on SUD-related behavioural effects of drugs, nicotine, and alcohol. The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A search was performed in PubMed and EMBASE on June 16, 2018. The inclusion criteria were primary studies investigating the use of GLP-1-receptor agonists on behavioural endpoints related to SUD. Seventeen studies were included, investigating the effect of the GLP-1-receptor agonists exendin-4, fluoro-exendin-4, liraglutide, AC3174 and GLP-1 (7-36) on SUD-related behavioural effects of ethanol, cocaine, amphetamine, and/or nicotine. All studies used rodents as subjects. Nine of the studies dealt with ethanol, six with cocaine, two with amphetamine, and two with nicotine. Most studies investigated acute treatment effects, finding a significant effect in all but one experiment. A few studies investigated more chronic effects on ethanol. All the studies reported sustained effects. Eleven studies tested more than one dose, finding a dose-related response in ten out of thirteen experiments. Six studies report a central effect through intra-cerebral administration or by using mice in which the central GLP-1-receptors had been inactivated. In conclusion, a solid body of evidence documents acute effects of GLP-1-receptor agonist treatment on behavioural effects of alcohol, nicotine, amphetamine and cocaine. Documentation of effect of more chronic GLP-1-receptor stimulation on these behaviours is limited.

Citing Articles

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.

Hendershot C, Bremmer M, Paladino M, Kostantinis G, Gilmore T, Sullivan N JAMA Psychiatry. 2025; .

PMID: 39937469 PMC: 11822619. DOI: 10.1001/jamapsychiatry.2024.4789.

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.

Radkhah H, Rahimipour Anaraki S, Roudsari P, Bahri R, Zooravar D, Asgarian S Eat Weight Disord. 2025; 30(1):10.

PMID: 39891848 PMC: 11787217. DOI: 10.1007/s40519-025-01720-9.

Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).

Klausen M, Kuzey T, Pedersen J, Justesen S, Rasmussen L, Knorr U BMJ Open. 2025; 15(1):e086454.

PMID: 39779270 PMC: 11749217. DOI: 10.1136/bmjopen-2024-086454.

Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.

Subhani M, Dhanda A, King J, Warren F, Creanor S, Davies M EClinicalMedicine. 2025; 78():102920.

PMID: 39764544 PMC: 11701477. DOI: 10.1016/j.eclinm.2024.102920.

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.

Qeadan F, McCunn A, Tingey B Addiction. 2024; 120(2):236-250.

PMID: 39415416 PMC: 11707322. DOI: 10.1111/add.16679.

References

Graham D, Erreger K, Galli A, Stanwood G . GLP-1 analog attenuates cocaine reward. Mol Psychiatry. 2012; 18(9):961-2. PMC: 3700649. DOI: 10.1038/mp.2012.141. View

Czoty P, Stoops W, Rush C . Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. Pharmacol Rev. 2016; 68(3):533-62. PMC: 4931869. DOI: 10.1124/pr.115.011668. View

Cork S, Richards J, Holt M, Gribble F, Reimann F, Trapp S . Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015; 4(10):718-31. PMC: 4588458. DOI: 10.1016/j.molmet.2015.07.008. View

Kalkhoran S, Benowitz N, Rigotti N . Prevention and Treatment of Tobacco Use: JACC Health Promotion Series. J Am Coll Cardiol. 2018; 72(9):1030-1045. PMC: 6261256. DOI: 10.1016/j.jacc.2018.06.036. View

Krauth D, Woodruff T, Bero L . Instruments for assessing risk of bias and other methodological criteria of published animal studies: a systematic review. Environ Health Perspect. 2013; 121(9):985-92. PMC: 3764080. DOI: 10.1289/ehp.1206389. View

Sorensen G, Reddy I, Weikop P, Graham D, Stanwood G, Wortwein G . The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav. 2015; 149:262-8. PMC: 4668599. DOI: 10.1016/j.physbeh.2015.06.013. View

Shirazi R, Dickson S, Skibicka K . Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One. 2013; 8(4):e61965. PMC: 3628574. DOI: 10.1371/journal.pone.0061965. View

Vallof D, Maccioni P, Colombo G, Mandrapa M, Jornulf J, Egecioglu E . The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2015; 21(2):422-37. PMC: 5049632. DOI: 10.1111/adb.12295. View

Jerlhag E . GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology. 2018; 136(Pt B):343-349. DOI: 10.1016/j.neuropharm.2018.01.013. View

10.

Sirohi S, Schurdak J, Seeley R, Benoit S, Davis J . Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav. 2016; 161:140-144. DOI: 10.1016/j.physbeh.2016.04.013. View

11.

Egecioglu E, Engel J, Jerlhag E . The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013; 8(10):e77284. PMC: 3799694. DOI: 10.1371/journal.pone.0077284. View

12.

Hernandez N, Ige K, Mietlicki-Baase E, Molina-Castro G, Turner C, Hayes M . Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology. 2018; 43(10):2000-2008. PMC: 6098066. DOI: 10.1038/s41386-018-0010-3. View

13.

Soyka M, Muller C . Pharmacotherapy of alcoholism - an update on approved and off-label medications. Expert Opin Pharmacother. 2017; 18(12):1187-1199. DOI: 10.1080/14656566.2017.1349098. View

14.

Thomsen M, Barrett A, Butler P, Negus S, Caine S . Effects of Acute and Chronic Treatments with Dopamine D and D Receptor Ligands on Cocaine versus Food Choice in Rats. J Pharmacol Exp Ther. 2017; 362(1):161-176. PMC: 5469403. DOI: 10.1124/jpet.117.241141. View

15.

Haney M, Spealman R . Controversies in translational research: drug self-administration. Psychopharmacology (Berl). 2008; 199(3):403-19. PMC: 2731701. DOI: 10.1007/s00213-008-1079-x. View

16.

Sorensen G, Caine S, Thomsen M . Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice. Alcohol Clin Exp Res. 2016; 40(10):2247-2252. PMC: 5048549. DOI: 10.1111/acer.13199. View

17.

Schmidt H, Mietlicki-Baase E, Ige K, Maurer J, Reiner D, Zimmer D . Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine. Neuropsychopharmacology. 2015; 41(7):1917-28. PMC: 4869061. DOI: 10.1038/npp.2015.362. View

18.

Egecioglu E, Engel J, Jerlhag E . The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013; 8(7):e69010. PMC: 3712951. DOI: 10.1371/journal.pone.0069010. View

19.

Thomsen M, Dencker D, Wortwein G, Weikop P, Egecioglu E, Jerlhag E . The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice. Pharmacol Biochem Behav. 2017; 160:14-20. DOI: 10.1016/j.pbb.2017.07.014. View

20.

Abtahi S, Howell E, Currie P . Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats. Neuroreport. 2018; 29(12):1046-1053. DOI: 10.1097/WNR.0000000000001071. View